179 related articles for article (PubMed ID: 32313567)
1. Inhibition of the Wnt/β-catenin pathway enhances antitumor immunity in ovarian cancer.
Doo DW; Meza-Perez S; Londoño AI; Goldsberry WN; Katre AA; Boone JD; Moore DJ; Hudson CT; Betella I; McCaw TR; Gangrade A; Bao R; Luke JJ; Yang ES; Birrer MJ; Starenki D; Cooper SJ; Buchsbaum DJ; Norian LA; Randall TD; Arend RC
Ther Adv Med Oncol; 2020; 12():1758835920913798. PubMed ID: 32313567
[TBL] [Abstract][Full Text] [Related]
2. Targeting the Wnt/β-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974.
Boone JD; Arend RC; Johnston BE; Cooper SJ; Gilchrist SA; Oelschlager DK; Grizzle WE; McGwin G; Gangrade A; Straughn JM; Buchsbaum DJ
Lab Invest; 2016 Feb; 96(2):249-59. PubMed ID: 26658453
[TBL] [Abstract][Full Text] [Related]
3. Inhibiting WNT Ligand Production for Improved Immune Recognition in the Ovarian Tumor Microenvironment.
Goldsberry WN; Meza-Perez S; Londoño AI; Katre AA; Mott BT; Roane BM; Goel N; Wall JA; Cooper SJ; Norian LA; Randall TD; Birrer MJ; Arend RC
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32213921
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Wnt/β-Catenin Signaling in Neuroendocrine Tumors in vitro: Antitumoral Effects.
Jin XF; Spoettl G; Maurer J; Nölting S; Auernhammer CJ
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32033025
[TBL] [Abstract][Full Text] [Related]
5. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
6. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
[TBL] [Abstract][Full Text] [Related]
7. Targeting of Wnt/β-Catenin by Anthelmintic Drug Pyrvinium Enhances Sensitivity of Ovarian Cancer Cells to Chemotherapy.
Zhang C; Zhang Z; Zhang S; Wang W; Hu P
Med Sci Monit; 2017 Jan; 23():266-275. PubMed ID: 28090074
[TBL] [Abstract][Full Text] [Related]
8. Intrinsic β-catenin signaling suppresses CD8
Xue J; Yu X; Xue L; Ge X; Zhao W; Peng W
Biomed Pharmacother; 2019 Jul; 115():108921. PubMed ID: 31078045
[TBL] [Abstract][Full Text] [Related]
9. The antitumor effects of entinostat in ovarian cancer require adaptive immunity.
Smith HJ; McCaw TR; Londono AI; Katre AA; Meza-Perez S; Yang ES; Forero A; Buchsbaum DJ; Randall TD; Straughn JM; Norian LA; Arend RC
Cancer; 2018 Dec; 124(24):4657-4666. PubMed ID: 30423192
[TBL] [Abstract][Full Text] [Related]
10. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
11. Blocking Wnt/β-catenin Signal Amplifies Anti-PD-1 Therapeutic Efficacy by Inhibiting Tumor Growth, Migration, and Promoting Immune Infiltration in Glioblastomas.
Zhang H; Bi Y; Wei Y; Liu J; Kuerban K; Ye L
Mol Cancer Ther; 2021 Jul; 20(7):1305-1315. PubMed ID: 34001635
[TBL] [Abstract][Full Text] [Related]
12. The dual pocket binding novel tankyrase inhibitor K-476 enhances the efficacy of immune checkpoint inhibitor by attracting CD8
Kinosada H; Okada-Iwasaki R; Kunieda K; Suzuki-Imaizumi M; Takahashi Y; Miyagi H; Suzuki M; Motosawa K; Watanabe M; Mie M; Ishii T; Ishida H; Saito JI; Nakai R
Am J Cancer Res; 2021; 11(1):264-276. PubMed ID: 33520373
[TBL] [Abstract][Full Text] [Related]
13. Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape.
Takeuchi Y; Tanegashima T; Sato E; Irie T; Sai A; Itahashi K; Kumagai S; Tada Y; Togashi Y; Koyama S; Akbay EA; Karasaki T; Kataoka K; Funaki S; Shintani Y; Nagatomo I; Kida H; Ishii G; Miyoshi T; Aokage K; Kakimi K; Ogawa S; Okumura M; Eto M; Kumanogoh A; Tsuboi M; Nishikawa H
Sci Immunol; 2021 Nov; 6(65):eabc6424. PubMed ID: 34767457
[TBL] [Abstract][Full Text] [Related]
14. WNT/β-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment.
Li X; Xiang Y; Li F; Yin C; Li B; Ke X
Front Immunol; 2019; 10():2293. PubMed ID: 31616443
[TBL] [Abstract][Full Text] [Related]
15. E7386, a Selective Inhibitor of the Interaction between β-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt Signaling.
Yamada K; Hori Y; Inoue S; Yamamoto Y; Iso K; Kamiyama H; Yamaguchi A; Kimura T; Uesugi M; Ito J; Matsuki M; Nakamoto K; Harada H; Yoneda N; Takemura A; Kushida I; Wakayama N; Kubara K; Kato Y; Semba T; Yokoi A; Matsukura M; Odagami T; Iwata M; Tsuruoka A; Uenaka T; Matsui J; Matsushima T; Nomoto K; Kouji H; Owa T; Funahashi Y; Ozawa Y
Cancer Res; 2021 Feb; 81(4):1052-1062. PubMed ID: 33408116
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer.
Arend RC; Londoño-Joshi AI; Samant RS; Li Y; Conner M; Hidalgo B; Alvarez RD; Landen CN; Straughn JM; Buchsbaum DJ
Gynecol Oncol; 2014 Jul; 134(1):112-20. PubMed ID: 24736023
[TBL] [Abstract][Full Text] [Related]
17. Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer.
Guo Z; Cheng D; Xia Z; Luan M; Wu L; Wang G; Zhang S
J Transl Med; 2013 Sep; 11():215. PubMed ID: 24044888
[TBL] [Abstract][Full Text] [Related]
18. Wnt inhibition alleviates resistance to immune checkpoint blockade in glioblastoma.
Jain R; Krishnan S; Lee S; Amoozgar Z; Subudhi S; Kumar A; Posada J; Lindeman N; Lei P; Duquette M; Roberge S; Huang P; Andersson P; Datta M; Munn L; Fukumura D
Res Sq; 2023 Dec; ():. PubMed ID: 38234841
[TBL] [Abstract][Full Text] [Related]
19. WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers.
Luke JJ; Bao R; Sweis RF; Spranger S; Gajewski TF
Clin Cancer Res; 2019 May; 25(10):3074-3083. PubMed ID: 30635339
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer.
Hartl CA; Bertschi A; Puerto RB; Andresen C; Cheney EM; Mittendorf EA; Guerriero JL; Goldberg MS
J Immunother Cancer; 2019 Jul; 7(1):199. PubMed ID: 31362778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
